Magyarország - magyar - OGYÉI (Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézetről)

sandoz hungária kft. - quetiapine -

Magyarország - magyar - OGYÉI (Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézetről)

sandoz hungária kft. - quetiapine -

Európai Unió - magyar - EMA (European Medicines Agency)

seqirus s.r.l.  - inaktivált influenza vírus felületi antigének: a / viet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - influenza vakcinák - az influenza profilaxisa a hivatalosan bejelentett pandémiás helyzetben. a pandémiás influenza vakcinát a hivatalos útmutatásnak megfelelően kell használni.

Európai Unió - magyar - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - az a / vietnam / 1194/2004 (h5n1) törzs influenzavírus-felületi antigénjei (hemagglutinin és neuraminidáz) - influenza, human; immunization; disease outbreaks - a vakcinák - aktív immunizálás az influenza a vírus h5n1 altípusa ellen. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

Európai Unió - magyar - EMA (European Medicines Agency)

takeda pharma a/s - ferumoxytol - anemia; kidney failure, chronic - egyéb vérszegénység elleni szerek - a rienso krónikus vesebetegségben (ckd) szenvedő felnőtt betegek vas-hiányos anémia intravénás kezelésére javallt,. a diagnózis a vashiányos alapján kell a megfelelő laboratóriumi vizsgálatok is (lásd 4.

Európai Unió - magyar - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - dermatitisellenes szerek, a kortikoszteroidok kivételével - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Európai Unió - magyar - EMA (European Medicines Agency)

ceva santé animale - megjegyzendő, vas (iii) - ion - megjegyzendő, kombinációk - sertés (malac) - az egyidejű megelőzés, a vashiányos vérszegénység, illetve megelőzése, a klinikai tünetek, a coccidiosis (hasmenés), valamint csökkenést a oocyst kiválasztás, a malacok a gazdaságok egy megerősítette, történelem, coccidiosis által okozott cystoisospora suis.

Európai Unió - magyar - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - a vakcinák - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Európai Unió - magyar - EMA (European Medicines Agency)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - a vakcinák - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. használja ezt a vakcinát a hivatalos ajánlásoknak megfelelően.

Európai Unió - magyar - EMA (European Medicines Agency)

zoetis belgium - bedinvetmab - fájdalomcsillapítók - kutyák - for the alleviation of pain associated with osteoarthritis in dogs.